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ABSTRACT

SEQUENCING THE GUTS OUT OF COVID-19; THE EVOLUTION
BEHIND THE COVID-19 PANDEMIC

Madelyn Grose Purnell
Biology Department
Bioinformatics

The global COVID-19 pandemic has led to an urgent need
for scalable methods for clinical diagnostics and tracking of virus
variants. In this paper, we attempted a novel method of sequencing
using Large Reverse Transcriptase-based cloning (LRTC).
Although our methodology ended up not working due to high
amount and fast degradation of RNA, we were able to sequence
multiple variants of COVID-19 Positive samples from the BYU
Student Health Center and 4 sewage samples to check for variant
outbreaks in corresponding times. We were able to find several
corresponding variants and track the progression of mutation in our
local population.
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CHAPTER 1 Introduction
The global COVID-19 pandemic has led to an urgent need
for scalable methods for clinical diagnostics and tracking of virus
variants. Thus far, the worldwide COVID-19 pandemic has resulted
in more than 6 million deaths and countless cases of permanent
side effects not to mention the social and economic hardships
associated with this outbreak. Hope is given through the rapid and
effective development of vaccines; however worldwide vaccine
distribution takes time. Virologists and epidemiologists are
concerned about the large number of variants arising worldwide
and the ability of one of these variants to break the vaccine barrier
or cause more serious or widespread disease. A better
understanding of how SARS-CoV-2 is evolving through variant
analysis is clearly needed. Our main goal is to contribute to this
understanding through the sequencing, analysis, and publication of
local variants. The BYU Student Health Center performed PCR
COVID-19 testing January 2021 – March 2022 and has saved over
100 positive samples for potential study, which we sequenced and
analyzed for variants. In addition, we used RNA obtained from
local sewage samples, which have been shown to reflect the
SARS-CoV-2 levels of a region (17, 20), as a second source of
SARS-CoV-2 variant analysis.
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One of the most perplexing qualities of many diseases is
their ability to affect individuals differently, and this is certainly the
case for COVID-19. Although COVID-19 is primarily a respiratory
disease, one of the more interesting aspects of COVID-19 is the
ability of it to become an intestinal disease in some persons (14). It
is currently unknown if this is due to particular variants causing
more intestinal disease, if the route of exposure (respiratory, ocular,
or ingestion) is the cause, or if it is a quality of the person’s
physiology (11). By comparing the variant frequency, we obtained
from Provo sewage to both the SARS-CoV-2 samples we
sequenced and the SARS-Cov-2 variant database (GISAID), we
may begin to answer this question. If the variants frequency in
sewage mirrors that of the Student Health Center samples, then our
hypothesis would be that intestinal SARS-CoV-2 is physiological or
by route of exposure. This could then be examined in future largerscale studies. However, if there is(are) variant(s) that are more
prominent in sewage than the Student Health Center samples, our
hypothesis would be that intestinal COVID-19 is caused by specific
SARS- CoV-2 strains.
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CHAPTER 2 Overview of the COVID-19 Pandemic
Origins
Until the beginning of the 21st century, coronaviruses (CoVs)
were considered to be minor pathogens for humans. However,
significant outbreaks in recent decades such as severe acute
respiratory syndrome (SARS) in 2002-2003 and the Middle East
respiratory syndrome (MERS) in 2012 have changed modern
perspectives on CoV’s (6). The most recent and well known severe
acute respiratory syndrome coronavirus (SARS-CoV) outbreak
occurred at the end of 2019. The virus has been identified from the
sequence-based analysis of isolates of various patients as a novel
coronavirus named SARS-CoV-2. The genome of the virus is
27kbp long and shares 80% nucleotide identity with that of human
SARS-CoV (28). Most experts believe SARS-CoV-2 originated from
bats, with the virus showing the highest nucleotide similarity to the
bat SARS (4).
The official respiratory disease caused by SARS-CoV-2 has
been declared as COVID-19, and the resulting wave of illness that
has spread across the world has been declared the COVID-19
pandemic. The original outbreak of COVID-19 originated in Wuhan,
China, and quickly led to the global pandemic (29). As the disease
has spread, new information regarding the clinical course of the
disease has emerged, along with new variants that have increased
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disease severity and provided new challenges to diagnostics,
treatment and vaccine development.
SARS-CoV-2 Variants
There are three major categories of viral disease: Variants of
Interest (VOI), Variants of Concern (VOC), and Variants of High
Consequence (VOHC). As the COVID-19 pandemic has evolved
through the last 2 years, we have seen many different strains
appear within the VOI-VOC range and spread worldwide. VOI’s are
typically limited in prevalence or expansion causing the main
concern to be in VOC’s, which are more commonly known.
VOCs are more dangerous due to their characteristic impact
on diagnostics, treatments, and vaccine development. Typically,
VOC’s have widespread interference with diagnostic tests and have
evidence of substantially decreased susceptibility to one or more
types of therapies. They also can show evidence of decreased
neutralization by antibodies generated during previous infection or
vaccination (evidence of reduced vaccine-induced protection). Also
in this category are strains with increased transmissibility and
evidence of higher virulence. COVID-19 has shown significant
expanse of variants within this category, with the most notable
including B.1.1.7 which originated from the United Kingdom in
September 2020 (known as alpha), B.1.351 from South America in
September 2020 (known as beta), P.1 from Brazil (known as
4

gamma) in December 2020, B1.427 from California (known as
epsilon) in March 2021, and B1.1.529 from South Africa (known as
Omicron) in November 2021 (22).
The rise of emerging variants can have many potential
consequences including the ability to spread more quickly in
people, or differences in the severity or symptoms of the disease.
Some of the potential consequences of emerging variants are the
following:
● Ability to spread more easily. There is evidence that one
mutation, D614G, increased the ability to spread more
quickly than the Wu-Han wildtype (5).

● Ability to cause either milder or more severe disease in
people. In January 2021, experts in the UK reported that
B.1.1.7 variant may be associated with an increased risk of
death compared to other variants. (25)

● Ability to evade detection by specific viral diagnostic tests.
Most commercial reverse-transcription polymerase chain
reaction (RT-PCR)-based tests have multiple targets to
detect the virus. Point mutations that interfere with primer
binding can decrease sensitivity.

● Ability to escape directed therapies. Decreased susceptibility
to therapeutic agents such as monoclonal antibodies.
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● Ability to evade natural or vaccine-induced immunity. Both
vaccination against and natural infection with SARS-CoV-2
produce a “polyclonal” response that targets several parts of
the spike protein. The virus would likely need to accumulate
multiple mutations in the spike protein to evade immunity
induced by vaccines or by natural infection, but some minor
changes in the capsid may cause decreased protection.
Among these possibilities, the last—the ability to evade vaccineinduced immunity—would likely be the most concerning because
once a large proportion of the population is vaccinated, there will be
immense pressure that could favor and accelerate emergence of
such variants by selecting for “escape mutants.” There is emerging
evidence that vaccines are no longer protecting against infection
and transmission in ongoing variants such as BA.5 (32).
Evolutionary Pressures
The way that selection is expected to act on new SARSCoV-2 variants is affected by the particular features of COVID-19,
including the extreme variability in disease presentation. Patients
with COVID-19 typically present fever, cough, or severe pneumonia
(4) with about 17% of cases never exhibiting symptoms
(‘asymptomatic’ cases), and yet they can still infect others, although
less often with a 42% lower transmission rate on average (3). Even
for those who exhibit symptoms, roughly half of the transmission
6

events are estimated to occur before individuals exhibit symptoms
(‘pre-symptomatic’ transmission) (23).
Most symptomatic individuals recover from COVID-19, but
even so, the infection fatality rate is high at about 0.68% globally
(19). In many infectious diseases, direct selection is expected to
reduce virulence over time (1), however, because severe
symptoms and mortality from COVID-19 typically occur weeks after
peak viral load-and this long after the peak transmission phase,
direct selection against virulence is expected to be extremely weak,
providing the ability to select for a more dangerous illness(9).
By contrast, selection strongly favors an increased
transmission rate in the early stages of a pandemic, when the
abundance of susceptible hosts is high (2). These general
predictions are also borne out in SARS-CoV-2-specific models,
which additionally show that selection favors shorter latent periods
prior to infectivity, higher infectiousness of asymptomatic
individuals, and prolonged infectious periods (9).
Evolution by mutation
Mutations arise as viruses replicate within an infected
individual, and thus new variants initially face selective forces within
that individual. For SARS-CoV-2, these within-individual
evolutionary processes have been best documented in
immunocompromised patients. These patients maintain high viral
7

loads over prolonged periods of time, allowing more opportunities
for viral replication and selection and leading to elevated
substitution rates. By sequencing the virus at multiple time points,
these studies have documented rapid changes to the composition
of the viral population within a patient, over the course of days (21).
A disproportionate fraction of mutations in many patients are
clustered in the gene encoding Spike, the protein that juts out of the
virus and binds to the ACE2 receptor that allows entry into host
cells (Fig. 2.1). Many of these mutations were found in the receptor
binding domain, which is essential for host entry. The concentration
of mutations occurring in the spike protein may reflect, in part,
relaxed selective constraints within immunocompromised
individuals, but many of these mutations are non-synonymous (7),
consistent with selection favoring changes to the Spike protein.
Furthermore, several mutations have arisen in parallel in different
patients, suggesting selection for those changes (18). These nonrandom patterns of genomic changes suggest that selective
pressures, alongside mutation, strongly shape viral evolution.
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Figure 2.1. A diagram of the lifecycle of SARS-CoV-2, showing
Spike protein interacting with the human ACE receptor for entry into
the cell. The virus exits the cell after assembly through budding.
SARS-CoV-2 binds to the ACE2 receptor which initiates entry into
the cell through membrane fusion. Once in the cell, the virus
uncoats and its +stranded RNA chromosome begins direct
translation as well as transcription of mRNA for protein synthesis,
and replication of more +stranded RNA for viral assembly. This
image was created by Vega Ansensio, copyright is held by Normate
Visual Science, and it is licensed and distributed for use under the
Creative Commons Attribution-Share Alike 4.0 International license.
We thank Vega Ansensio for his contributions.
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COVID-19 Tracking
There have been over 500 million confirmed cases of
COVID-19, as of July 14, 2022, including 6,356,812 deaths, and
affecting at least 230 countries. (WHO, https://covid19.who.int/).
Variants of concern (VOC) with increased transmissibility are
contributing to the reversal of the decreases in Covid-19 case
counts that occurred in many countries from the past couple of
years (Figure 2.2). The BA.5 (Omicron) variant of concern
increases viral transmissibility (32) and is emerging as an
increasingly common variant in 2022. The P.1 (or gamma) variant
may cause severe disease even in persons who have been
previously infected, although definitive information is lacking (10).
The B.1.351 (or beta) variant is less easily neutralized by
convalescent plasma obtained from patients infected with previous
variants and by serum obtained from vaccinated individuals than
the prototype virus on which vaccine antigens are based (10).
Preliminary evidence (based on data from posthoc subgroups in
placebo-controlled vaccine trials) suggests reduced efficacy of
some vaccines against mild or moderate disease caused by this
variant (15). Additional variants that are responsible for many
deaths, such as B.1.617.2 (or delta), continue to emerge. So far,
there is good evidence that most previously identified VOCs evade
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the most important vaccine effect— that of prevention of severe
disease. However, new rise in Omicron Variant BA.5 has shown a
high increase in fatalities despite the high vaccine coverage and
prior variants (32).

Figure 2.2. A timeline of the occurrence of several SARS-Cov-2
variants of concern (VOCs). The common names of the variant
are provided along with the likely country of origin and the number
of base pair changes in the spike protein.

Variant tracking
Efforts to track viral mutations and variants are ongoing. The
aim is to detect novel changes quickly and to assess their possible
effects on diagnosis, transmission, disease symptoms and severity,
treatment and vaccine efficacy. Many research groups are
sequencing virus isolates and sharing these sequences on public
databases such as GISAID (Global Initiative on Sharing All
Influenza Data). This collaboration helps scientists track the ways in
which the virus is evolving. In order to help monitor and respond to
the evolving pandemic, it is important that all countries increase the
collection of virus isolates for sequencing and sharing. A SARS-
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CoV-2 risk-monitoring and evaluation framework is being
developed and continually improved by the WHO to identify and
assess variants of concern. This framework, which involves
enhanced surveillance, research on variants of interest and variants
of concern, and evaluation of the effect of variants on diagnostic
tests, therapeutic agents, and vaccines, will assist in global
decision-making regarding changes in vaccines that may be
necessary (13).
In addition to continuing to track the emergence of new
SARS-CoV-2 variants, there are four major priorities for the global
response to variants of concern. These priorities, which involve
scientific approaches for evaluating existing vaccines and
developing modified and new vaccines, are to determine whether
existing vaccines are losing efficacy against variants, to decide
whether modified or new vaccines are warranted to restore efficacy
against variants, to reduce the likelihood that variants of concern
will emerge, and to coordinate international research and the
response to new variants, both in general and in relation to
vaccines, through the (WHO).
Wastewater-based disease surveillance
The COVID-19 pandemic has had profound impacts on the
day-to-day life of millions of individuals around the world due to
illness, death, and both economic and social effects of the
12

lockdowns. COVID-19 surveillance approaches invoked by nations
around the world include case ascertainment of individual patients,
nucleic acid-based test, contact tracing, and Wastewater-based
epidemiology (WBE).
WBE is a relatively novel epidemiological technique that has
been used by public health authorities for decades to track trends in
the general population for numerous diverse substances such as
illicit and recreational drugs (12), toxic and harmful chemicals and
pesticides (16), as well as prevalence of disease and illness (31).
One of the major advantages of WBE is that with welldesigned sampling/testing regimes, it can be utilized to gain
valuable, and sometimes otherwise unobtainable information for
subsets of population, as small as a single building or
neighborhood, or as large as a city or county (24). As such, WBE
has been investigated as a potential surveillance tool to obtain a
rapid measure of the relative incidence rate of COVID-19 infections
in the population at large, generating an entirely new
epidemiological metric for public health units (PHU) to utilize.
Fecal shedding of SARS-CoV-2 viral particles has been
shown to occur before, during and after active COVID-19 infections,
for periods ranging from a few days to several weeks (4).
Additionally, fecal shedding of SARS-CoV-2 viral particles in stool
appears to be independent of the presence of SARS-CoV-2 viral
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particles in the upper respiratory tract (24). Meaning that different
viral loads are affecting the digestive system, opposed to the
respiratory system.
Studies to date that demonstrate the potential for WBE to
identify the onset of community infection prior to clinical testing
have primarily been applied to identifying the first wave of the
disease in the community (30). During the pandemic several
studies thus far have shown WBE to be a useful tool for identifying
waves of COVID-19 in local communities (8,24).

Conclusions
The rapid evolution of SARS-CoV-2 combined with its
worldwide presence and high caseloads suggests mankind will be
battling for control of this virus for decades to come. A key to
developing effective strategies for its control is to understand its
evolutionary trajectory. Mass sequencing of SARS-CoV-2 and
analysis of the evolutionary changes are pivotal to this
understanding. Herein we seek to provide techniques for strain
analysis in sewage samples, as well as to follow the progression of
SARS-Cov-2 in our local population through sequencing of both
individual positive cases at BYU and local sewage samples.
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CHAPTER 3 Attempting to Sequence Complex COVID-19
Samples with Large Reverse Transcriptase-based Cloning
(LRTC)
Introduction
Although wastewater has been used to track several
diseases and has even helped predict the onset of COVID-19
infection waves, it is an untapped resource for understanding the
evolution of SARS-CoV-2 strains. This is because wastewater is a
mixed sample of strains from thousands of people in most cases,
and most sequencing strategies are based on a single isogenic
sample. Our goal herein is to test the use of Long Reverse
Transcriptase Cloning for the isolation and sequencing of single
SARS-CoV-2 genomes from a mixed population.
The SARS-CoV-2 virus is composed of a single RNA
genome that is approximately 27kb (26). In order to sequence
SARS-CoV-2 the RNA needs to be converted to DNA, however
there is no reverse transcriptase known that will fully replicate all
27kb of the genome. Currently, the most common protocol to
sequence SARS-CoV-2 variants is using the ARTIC network
(Figure 3.1A) which relies on first strand synthesis using random
and or oligo dT primers, followed by direct amplification of the virus
15

using tiled, multiplexed primers that amplify little pieces (150-400
bp) of the genome (26). Within these fragments there is overlap
which allows for the genome to be reassembled to reveal the full
SARS-CoV-2 genome sequence. The problem with ARTIC
sequencing is that you must have a purified isolate of the virus
since you are reconstructing hundreds of fragments back into one
genome. This poses a problem if we are sequencing a mixed
population containing tens, hundreds or even thousands of different
SARS-CoV-2 variants such as seen in wastewater samples.
To combat this problem, we attempted to develop a novel
protocol that we had entitled Large Reverse Transcriptase Cloning
(LRTC). LRTC would use SuperScript IV Reverse Transcriptase
(New England Biolabs, NEB) that allows for up to 13kb to be
converted to cDNA, dividing the RNA genome into 3 overlapping
13kb pieces instead of the hundreds produced by ARTIC. These
13kb pieces would be individually sequenced, allowing multiple
variants to be able to be associated with a single SARS-CoV-2
genome/strain. After the reverse transcriptase had converted the
RNA into 13kb cDNA pieces, Phusion High fidelity DNA polymerase
(NEB) would be used to synthesize the second strand. These
individual fragments of cDNA would then be cloned into plasmid
pMINIT using NEB’s PCR Cloning Kit. Colonies arising from the
molecular cloning each harbor one plasmid containing one 13kb
16

fragment of one SARS-CoV-2 genome. These colonies would then
be individually picked, their plasmid purified, and each would be
given a unique barcode when performing standard Next Generation
Sequencing (NGS) library construction (NEBNext Ultra II DNA
Library Prep). Once sequenced on the Illumina MiSeq and
assembled using Geneious software, the 13kb contigs would allow
us to recreate the entire viral genome of our sample strains due to
the overlapping nature of the three 13kb fragments originally
obtained. However, in any case, our LRTC protocol would allow for
variants arising within a 13kb region to be associated with a single
genome/strain of SARS-CoV-2. This would be extremely valuable
when dealing with complex samples.
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Figure 3.1. Comparison of the standard “ARTIC” strategy (A) with our large fragment
cloning strategy (B), termed “Long Reverse Transcriptase Cloning (LRTC)” strategy for
SARS-CoV-2 sequencing.
The standard ARTIC protocol, first strand synthesis is
performed using random and or oligo dT which results in random
smaller fragmentation of the genome. First strand synthesis is
followed by cDNA synthesis through direct amplification using tiled,
multiplexed primers that amplify little pieces (150-400 bp) of the
genome (26). In the Long Reverse Transcriptase Cloning Strategy
primers were designed to amplify overlapping 13 Kbp pieces of the
genome in both the first strand synthesis and dna amplification
steps. Large fragments are then cloned, and library prepped for
individual sequencing.
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RT-PCR, QPCR, & primer creation for three overlapping
11,000-12,000 bp amplicons
Before using the RNA collected from the raw influent
wastewater SARS-CoV-2 RNA extraction samples, we decided to
collect and use direct SARS-CoV-2 RNA extracted from Rich
Robinsons BYU BSL3 lab. This direct SARS-CoV-2 sample is nondiluted, meaning that it should work as a positive control for our
method protocol. We also prepared a 10x dilute of the SARS-CoV-2
sample as a separate control to test whether our sewage samples
(which could have far greater dilution) could even work in our
protocol. The Rich Robinson SARS-CoV-2 sample was assessed
previously with a spike gene amplification protocol specific for WuHan 1 isolate, SARS-CoV-2 and was found to amplify beautifully,
making it a good test for the protocol.
We conducted first strand synthesis on one sample from the
fully concentrated sample and diluted sample of SARS-CoV-2 using
ThermoFisher Scientific SuperScript IV VILO Master Mix with
ezDNase Enzyme to digest alternative sources of DNA that may be
present in the sample. For the protocol we initially annealed the
primer to the template RNA by mixing SARS-CoV-2 specific
primers for reverse transcriptase. The primers were constructed
from the Wuhan-Hu-1 SARS-CoV-2 isolate complete genome
sequence (GenBank MN908947.3). The reverse primers were
19

chosen at 11141bp, 19920 bp, and the very end of the sequence
creating regions of ~12000-13000 bp (Table 3.1). Forward primers
were selected allowing for overlap between the pieces (Fig. 3.1).
The oligos were calculated using Northwestern University's
Oligonucleotide properties calculator biotool. All of the oligos had a
salt adjusted temperature between 61° C & 66° C with no potential
hairpin formations, 3’ complementary, or potential self-annealing
sites (OligoCalc.com).
Table 3.1 Primers designed to amplify 11,000-12,000 overlapping
bp fragments of SARS-CoV-2 by reverse transcriptase and then
PCR.

To set up Polymerase Chain Reaction (PCR) we decided to
divide each RNA sample into two separate runs to test whether Q5
DNA Polymerase or Phusion DNA Polymerase would be more
beneficial for our protocol since previous publications alluded that
both work for larger base pair pieces (reaching ~11kbp in other viral
genomes and reaching ~5kbp in SARS-CoV samples), but because
20

these are far longer segments that we are striving for, we wanted to
test to see if one happened to work better than another. We also
made sure to keep separate tubes for each set of primers so that
we wouldn’t risk one outcompeting the others during PCR. To
better limit DNA contamination, we also prepared the samples with
gDNA digestion. We also performed standard controls using the
NEB standard control kit that comes with the PCR amplification.
We then reviewed the PCR protocol as instructed for basic
Q5 and Phusion PCR. Upon review, we decided that to better
ensure proper annealing we would increase that standard Phusion
PCR to hold at 60 °C for 45 seconds rather than the 30 seconds to
make sure the annealing time was sufficient.
After the PCR we ran Gel Electrophoresis on the cDNA
product to analyze the size of our product. We found that there was
cDNA being produced but in short fragments (~500bp) meaning
that the cDNA was not long enough for our desired full template
size (~12kb) (Fig.3.2). We did not believe this to be a polymerase
problem due to the negative and positive controls working as we
had hoped, and the streaking we see in our product gel which
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indicates it is trying to make larger pieces but is not doing so
successfully.

Figure 3.2 Gel Electrophoresis run on RT-PCR product
showing cDNA being produced in short fragments showing
that likely the RT cDNA is not long enough or the desired
template size of ~12-13 kb. Lane 1 is NEB 1 Kb ladder, lanes
2-4 are the three fragments (11141, 10920, 11014 bp
respectively) using SARS-CoV-2 RNA undiluted, Phusion
polymerase. Lanes 5-7 are the three fragments using the
10X dilutions of SARS-CoV-2 RNA, Phusion polymerase,
Lanes 8-10 are the three fragments (1-3 respectively) using
SARS-CoV-2 RNA 10X Diluted, Q5 polymerase. Lanes 1113 are the three fragments using the undiluted SARS-CoV-2
RNA, Q5 polymerase. Red Top Arrow shows where we were
expecting to see banding. Red Bottom arrow indicates extra
primers and dye on the bottom.

To allow for more time for the PCR to produce a larger
product, we decided to change our protocol. We then began first
strand synthesis again, but decided that when reverse transcribing
the RNA, we would incubate the sample at 50°C for 50 minutes
opposed to 30 minutes to give the RT-PCR more time to create
larger product and achieve longer cDNA templates. 50 minutes was
22

our chosen time frame after reading through “Robust cDNA
synthesis is Achieved even with Longer Templates” on the NEB RT
information page. We then performed Q5 and Phusion HF PCR
reactions.
The Gel Electrophoresis run from the product yielded better
results or larger products approaching ~12kbp in the middle region
due to the changes made in first-strand synthesis (Fig. 3.3). Larger
template strands can be seen, but it still does not seem to reach the
optimal length. I re-examined the primer ™ calculations and
realized that both the Q5 and Phusion polymerase annealing
temperatures are lower than recommended, though I was unsure if
the lower temperature was the problem (since normally you worry
about temperatures being too high when there is no product), we
decided to try the higher temperature.
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Figure 3.3 Gel Electrophoresis run on PCR sample products. The gel
run was faint but yielded better results due to the changes made in the
first strand synthesis. Larger template strands can be seen but are not
optimal. BOTTOM: Lane 1 is NEB 1 Kb ladder, lanes 2-4 are the three
fragments (11141, 10920, 11014 bp respectively) using SARS-CoV-2
RNA undiluted, Phusion polymerase. Lanes 5-7 are the three fragments
using the 10X dilutions of SARS-CoV-2 RNA, Phusion polymerase,
Lanes 8-10 are the three fragments (1-3 respectively) using SARS-CoV2 RNA undiluted, Q5 polymerase. Lanes 10-12 are the three fragments
using the 10X dilutions of SARS-CoV-2 RNA, Q5 polymerase. TOP:
Lane 1 is NEB 1 Kb ladder, lanes 2-4 are the three fragments (11141,
10920, 11014 bp respectively) using SARS-CoV-2 RNA undiluted,
Phusion polymerase without ezDNase enzyme to see if it changed
outcomes. Lanes 4-6 are the three fragments using the 10X dilutions of
SARS-CoV-2 RNA, Phusion polymerase without ezDNase enzyme to
see if it changed outcomes. It did not.
Investigating optimal primers, reverse transcriptase and DNA
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Investigating optimal primers, reverse transcriptase and DNA
polymerase enzymes
Based on our previous gel run we saw that the beginning
and end sections didn’t seem to be amplifying while the middle
section (9000bp-19920bp) was the only one consistently producing
large products. For the end section, we believed we could be
asking for too much of the polymerase since we included the polyA-tail into our initial end primer which could be causing further
issues by binding other poly-A-tailed RNA’s that are in the sample.
We initially included the tail because it would be useful to have the
entire genome, but due to this error we re-ordered another reverse
primer that did not include the tail to see if that yielded a better
product. For the beginning primer, we were wondering if our
Reverse Transcriptase was making it all the way through the RNA
section due to it not only being the longest piece, but our forward
primer begins at the first base pair which could have been easily
stripped due to instability of the RNA. To fix this problem, we
ordered a second reverse primer to make the forward section
shorter. Another precaution we conducted was another run using
different reverse transcriptase enzymes (SuperScript IV and
ImProm-II) both known for their high processivity).
Because we could see the 10x dilution RNA was working,
we were more optimistic moving forward with the sewage RNA
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samples since we could at least see some ~12kbp product being
produced.
For first strand synthesis, we used our 3 main reverse
primers (11140R bp, 19920R bp, and endReverse bp), but we used
the new end primer which does not include the poly-A-tail (labeled
4880R). For first strand synthesis we moved forward with testing
the wastewater sewage samples and also decided to use two
different reverse transcriptase’s to see if one worked better than the
other. We used SuperScript IV Vilo Master Mix protocol as well as
ImProm-II RT. We followed the exact outline of the ImProm-II ™
reverse transcription system TM236 experimental reaction. For the
PCR we chose Q5 polymerase since there had been no indication
of one working better than another for a standard.
Upon initial evaluation of the proceeding gel (Fig. 3.4), it
appeared that ImProm-II RT was less effective than the SuperScript
IV. The new end primer that excluded the poly-A-tail also did not
appear to improve our method. Longer lengths that should have
been detected were not, meaning that we are not reaching our
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desired length outcome, suggesting we needed smaller-sized
fragments.

Figure. 3.4 Gel electrophoresis results from amplification of SARSCoV-2 from sewage using two different reverse transcriptase
enzymes. Lane 1-3 features sewage sample using ImProm-II RT.
Lane 4 features the DNA ladder. Lane 5-7 features sewage sample
using SuperScript IV. Red Arrows signify where we should be
seeing banding ~11,000 bp. Bottom of each lane is dye or primer
leftovers, while main banding is at ~200 bp. Smearing on lane 6
suggests ~1k bp.

Amplification with primers designed to retrieve six SARS-CoV2 amplicons
Our results indicated that we needed to change our
methodology completely. The larger sections of DNA were not
being amplified even with all the changes made, suggesting that
instead of splitting the genome into three very large pieces (11,00027

12,000 bp), split into a six-piece methodology (2,000-9,300 bp) with
new primers to create less of a strain on the polymerases. The
details of this design are presented in Tables 3.3 along with Figure
3.5. The primers were chosen to try to create smaller base pair
sections while not being in the middle of documented genes,
resulting in non-uniformed length pieces. In addition, they were
designed at different lengths based on our previous results, which
indicated difficulties in PCR amplification of select regions. Each
primer was checked for proper Oligonucleotide properties (melting
temperature of 60-65° C, lack of self -annealing).

Table 3.3 Primers designed to amplify six 2,000-9,300 bp
overlapping fragments of SARS-CoV-2 by reverse transcriptase
and then PCR. Amplicons are of variable lengths due to the
differential degree of difficulty in amplifying various regions of
SARS-CoV-2 and the desire to avoid primers within genes,
possibly obscuring the detection of mutations/variants.
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Figure 3.5 Diagram illustrating the forward and reverse primer pairs
for SARS-CoV2 amplification as six fragments/amplicons.

Because the SuperScript IV RT appeared to outperform the
other reverse transcriptase it was used as the only reverse
transcriptase for first strand synthesis in all subsequent reactions.
For PCR, Phusion HF polymerase appeared to be superior and
was used in a 50 μl reaction with 5 μl of template cDNA (see NEB
protocol). Products were run on gel electrophoresis and are
presented in Figure 3.6.

Figure 3.6 Gel electrophoresis results of amplification of SARSCoV-2 as six overlapping fragments from sewage yield primarily
smeared bands. Primers used are described in Table 3.3. Lane 1:
1Kb ladder used standards (NEB), Lane 2: 1bp-8554bp
amplification reaction, Lane 3 806 bp – 10054bp amplification
reaction, Lane 4 9000bp-13442bp amplification reaction, Lane 5
13025bp-19920bp amplification reaction, Lane 6 18901bp-28259bp
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amplification reaction and Lane 7 27894bp-end amplification
reaction. Red Arrow indicates the base pair Length we were aiming
to see. We see smearing in that area in all lanes except 5.

After performing the protocol again and adding NEB basic
controls as well as various amounts of primer (with adding 25%
less and 50% less), we came up with no further conclusions.
Although RNA extraction from the wastewater appeared to be
successful due to the presence of some bands among the smeared
product, the lack of large discrete bands suggests our method is
still not optimal. Thus, we re-evaluated the primers again, this time
not worrying about separating genes in order to create fairly
uniformed 5K-6K bp regions.
Amplification with primers designed to retrieve five uniform
SARS-CoV-2 amplicons
New primers were designed from Wuhan-Hu-1 isolate
(GenBank MN908947.3) and retained a relative TM Salt Adjusted
value of 65 with no potential hairpin loops, no 3’ complementarity,
and no potential self-annealing sites in the sequences
(Oligonucleotide Properties Calculator). This created 5 regions
between 6K-7K bp long with similar length of overlapping sections
(Table 3.4 and 3.5, Figure 3.7).
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Table 3.4 Primers designed to amplify five uniform overlapping
fragments of SARS-CoV-2 by reverse transcriptase and then PCR

Table 3.5 Primers designed to amplify five uniform overlapping
fragments of SARS-CoV-2 by reverse transcriptase and then PCR.
Regions are specified in Table 3.4.

Figure 3.7 Diagram illustrating the forward and reverse primer pairs
for SARS-CoV2 amplification as five fragments/amplicons fairly
uniform in length.
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The resulting gel didn’t show strong bands at the expected
sizes; however, it did yield larger fragments of almost the expected
size in each case (Fig. 3.8). Because there are streaks through the
desired bp size region, we decided to move forward with our
methodology by cutting out that region of the gel and cloning,
hoping to retrieve the desired fragments.

Figure 3.8 Gel electrophoresis results of amplification of SARSCoV-2 as five fairly uniform overlapping fragments from sewage
yield primarily smeared bands of larger fragment size. Primers used
are described in Table 3.4. Lane 1: 1 Kb ladder used standards
(NEB), Lane 2: 1bp-6016bp amplification reaction, Lane 3 5529bp –
11858bp amplification reaction, Lane 4 11333bp-17882bp
amplification reaction, Lane 5 17319bp-23878bp amplification
reaction, and Lane 6 23296bp-29898bp amplification reaction. Red
Arrow indicates where we were hoping to see banding. No banding
is seen, but smears are reaching the intended area in all lanes.
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Cloning of potential SARS-CoV-2 amplicons
The 5kb products from Fig. 3.6 were cut from the low melt
gel and ligated into plasmid pMINIT using the NEB PCR Cloning kit
(#E12025) to attempt molecular cloning. We followed the ligation
protocol stated in the kit instructions and then proceeded to
immediately transform in E. coli (Invitrogen). Transformed cells
were plated on LB+AMP plates following a 30-minute recovery, and
plates were incubated overnight at 37° C. Potential clones were
then picked for colony PCR using TAQ polymerase. PCR products
were run on gel electrophoresis to determine if the correct size of
DNA had properly been inserted (Figure 3.9).
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Figure 3.9 Gel electrophoresis results of amplification of the pMINIT
multiple cloning site indicated a lack of 5 kb SARS-CoV-2 inserts.
Lane 1 top and bottom (NEB 1 Kb ladder). Lane 2-14 top and
bottom are of colonies retrieved from cloning ~5 Kb bands. Red
arrow signifies where we should see the insert band. None was
found at that size indicating this methodology did not work.
From the gel, we could tell that this method wasn’t working
as we had hoped, however several of the colonies appeared to
have fairly long products (3 kb).
Conclusions
Throughout our study, the largest consistent fragments
obtained were 3 Kb, with many regions unable to amplify well. The
3kb product size would place SARS-CoV-2 into 10 fragments,
making this method of little use in our desire to sequence almost
complete genomes of SARS-CoV-2 in complex samples. Our
results suggest SARS-CoV-2 RNA is highly unstable. From this,
we realized that due to the beginning and end of our DNA being so
heavily damaged it was unlikely to use this method to perform
whole genome sequencing. As such, we concluded that this
method was unlikely to produce the results we are looking for, so
we proceeded with sequencing the positive COVID-19 samples and
designated wastewater samples via standard protocol. Future work
could focus on different primers, different reverse transcriptase
enzymes and conditions, etc. to try to extend beyond the 3 Kb
mark.
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CHAPTER 4 Sequencing Samples
Introduction
The COVID-19 pandemic has claimed more than 6 million
lives worldwide and is now considered to be endemic by most
experts, meaning that we must learn to effectively control its impact
for potentially decades to come. This is challenging given the rapid
evolution of the virus, both due to the large number of infected
persons and the high viral load. This rapid evolution is dangerous
as have shown that in contrast to many pathogens, SARS-CoV-2,
the causative agent of COVID-19, appears to be evolving increased
pathogenicity in several of the emerging evolutionary lines. This is
likely due to high viral shedding even before a person displays
symptoms, allowing it to spread to others long before making its
original host sick. Thus, experts must consider many factors in
SARS-CoV-2 control including diagnostics for early detection,
optimization of vaccines and treatments, and slowing the evolution
of novel pathogenic strains that escape these controls. A key in
these studies is understanding the evolutionary trajectory of SARSCoV-2.
To understand the evolution of SARS-CoV-2., many studies
have reported the full genome sequencing and analysis of
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mutations/variants in a population, leading to the identification of
several key variants of concern (VOCs). Some of the most notable
include the B.1.1.7 (or alpha) which increases viral transmissibility
(27), the beta (or B.1.351) variant which is less easily neutralized
by convalescent plasma, the delta ( B.1.617.2) and Omicron
mutants which may have higher transmissibility, and the gamma
variant (P1) which may cause severe disease even in persons who
have been previously infected (10).
To contribute to the understanding of SARS-CoV-2
evolution, herein we report the whole genome NGS sequencing on
a subset of the positive COVID-19 samples from Brigham Young
University from September 2021- April 2022.
Results
Random positive samples were chosen from the BYU
student health center to represent the positive cases from
September 2021-March 2022. A pipeline diagram of our
sequencing efforts is provided in Figure 4.1. Briefly, samples are
chosen at random from the positive COVID-19 cases. Plates
containing these samples are thawed and samples are carefully
aliquoted from the plates with a filter tip pipet tip and transferred to
a PCR tube using RNase Away to inhibit degradation during
extraction. Positive samples were then used as template for first
strand synthesis using random hexamer primer, followed by PCR
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amplification with IDT’s xGen SARS-CoV-2 Amplicon panel, a set
of 345 multiplexed primers for overlapping amplicons, and library
preparation using the IDT xGen Amplicon Core library prep kit with
xGen Amplicon Index plate 1 and plate 2. Libraries are checked by
quantification of each individual sample as well as bioanalyzer
analysis of some random samples to check length and purity prior
to pooling and running 150 bp paired-end sequencing on the
Illumina MiSeq (The BYU Department of Microbiology and
Molecular Biology Sequencing Center, 3006 LSB).

Figure 4.1. A diagram of the sequencing strategy flow for BYU
SARS-CoV-2 RNA samples.
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Sequencing BYU SARS-CoV-2 Round 1
A summary of the initial 137 samples that were subjected to
library prep and sequencing are provided in Table 4.1. Library prep
was performed using Moloney Murine Leukemia Virus reverse
transcriptase (MMLV reverse transcriptase, Takara Biotech) for the
first strand DNA synthesis, with a synthesis time extended to 60
minutes. Quantification of the individual samples from the library
prep was performed using the AccuBlue dsDNA High Sensitivity
Quantitation Kit (Biotium) and is also provided (see Table 4.1 and
Figure 4.2) with a summary of the random bioanalyzer analysis of
eleven random samples provided in Figure 4.3. The bioanalyzer
confirmed the size fragments averaged 130 bp for most samples
and was higher for some (150 bp was expected for all), and the
quantity was low but acceptable for sequencing (~1 ng/uL or 10 nM
per sample). Samples were pooled by diluting all to 1 nM and
pooling 5 uL of each. This 1 nM pooled library was then denatured
for 5 minutes with 0.2 N NaOH prior to diluting to 20 nM and
injecting on the MiSeq using cartridge v2.
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Table 4.1 General properties and library preparation quantification for
128 positive SARS-CoV-2 samples from the Brigham Young
University Student Health Center. “#” is the RNA sample number, the
sample date is the day the sample was taken and prepped by the
BYU Student Health Center. The “Abs 480/530” is the absorbance
from the AccuBlue dsDNA High Sensitivity Quantitation Kit (Biotium),
“Backgrd. Correction” is correction for the absorbance of the elution
buffer only, and ug/mL comes from the fit of the standard curve
shown in Figure 4.2. The nM conversion is from the equation “ “. The
uL 1 nM stock uL is the uL needed to make a 1 nM stock when
combined with the uL of water. The i5 index and the i7 index from the
dual indexing library prep is also provided.
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Figure 4.2 Standard curve for the quantification of dsDNA using the
AccuBlue dsDNA High Sensitivity Quantitation Kit (Biotium). A
scatter plot is shown, and a linear fit equation is provided which
was used to calculate ds DNA concentrations.
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Figure 4.3. Bioanalyzer analysis of the size, purity and quantity of
11 random SARS-CoV-2 samples. A) Image of the capillary gel run
of all 11 samples. B & C) Peak images and quantification of two
samples, sample 107 and 121. D) Sample peak images of all 11
samples. Samples were run on the DNA Bioanalyzer at the
Brigham Young University DNA Sequencing Center housed in the
Life Sciences Building (LSB).
Unfortunately, although the bioanalyzer results looked
promising both for the expected size and concentration, the
sequencing results were poor. Illumina reported poor occupancy
statistics for the sequencing run (%Q30 Read 1 82.8%, %Q30
Read 2 73.3%, % ClustersPF 41.4% and %Occupancy 43.1%). In
addition, the average number of reads per sample was less than a
thousand, far too little to assemble the complete genome using
Geneious 8.0 de novo assembly, however small fragments did align
suggesting we did amplify the SARS-CoV-2 genome. Clearly a
better library preparation needed to be performed.
Sequencing BYU SARS-CoV-2 Round 2
Due to our previous experience with SARS-CoV-2 RNA
instability, we hypothesized that the poor sequencing results were
due to instability. To test this, we performed RNA extraction from
plate, first strand synthesis and even DNA library preparation all in
one day on 14 samples not tested before as well as four sewage
samples we had collected from the Provo water treatment plant,
immediately isolated the RNA from and froze (Table 4.2). At the
library preparation step, we added 30 samples from the first library
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preparation, and performed new reverse transcription on 15 of them
just in case our first reverse transcriptase reactions were
suboptimal (Table 5.1). We also switched reverse transcriptase
enzymes to use Superscript IV and mixed in an oligo dT primer with
the random hexamer primer (another suggestion to enhance
genome coverage found in several recent SARS-CoV-2 sequencing
protocols). Both MMLV and SuperScript IV are abundant in SARSCoV-2 sequencing protocols and manuscripts. This trial supports
our hypothesis that it is the RNA instability giving rise to poor library
preparation in that the samples pulled fresh from the freezer
(unhighlighted in Table 4.2) were 10-100 times more concentrated
than the previously used RNA samples. Only these 14 samples
were diluted to 1 nM and prepared for sequencing, however more
samples were needed.
Table 4.2 Testing RNA stability through DNA library preparation of
SARS-CoV-2 samples. General properties and library preparation
quantification for 48 positive SARS-CoV-2 samples from the
Brigham Young University Student Health Center. Samples with
light gray highlight were from sequencing round 1 cDNA, darker
gray highlight indicates samples from sequencing round 1 that were
subjected to new first strand synthesis, and unlighted new samples
were freshly retrieved from the freezer. “#” is the RNA sample
number, the sample date is the day the sample was taken and
prepped by the BYU Student Health Center. The “Abs 480/530” is
the absorbance from the AccuBlue dsDNA High Sensitivity
Quantitation Kit (Biotium), “Backgrd. Correction” is correction for the
absorbance of the elution buffer only, and ug/mL comes from the fit
of the standard curve shown in Figure 4.2. The nM conversion is
from the equation “ “. The uL 1 nM stock uL is the uL needed to
make a 1 nM stock when combined with the uL of water. The i5
index and the i7 index from the dual indexing library prep is also
provided.
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Figure 4.2 Standard curve for the quantification of dsDNA using the
AccuBlue dsDNA High Sensitivity Quantitation Kit (Biotium). A
scatter plot is shown, and a linear fit equation is provided which
was used to calculate ds DNA concentrations.
Due to the success of library preparation on samples pulled
fresh from the freezer, we choose another 33 samples randomly
throughout the year to add to the sequencing run. This library was
also prepared in a single day just as the 14 previous samples had
been. The results were again successful (Table 4.3).
Table 4.3 General properties and library preparation quantification
for 29 positive SARS-CoV-2 samples from the Brigham Young
University Student Health Center. “#” is the RNA sample number,
the sample date is the day the sample was taken and prepped by
the BYU Student Health Center. The “Abs 480/530” is the
absorbance from the AccuBlue dsDNA High Sensitivity Quantitation
Kit (Biotium), “Backgrd. Correction” is correction for the absorbance
of the elution buffer only, and ug/mL comes from the fit of the
standard curve shown in Figure 4.2. The nM conversion is from the
equation “ “. The uL 1 nM stock uL is the uL needed to make a 1
nM stock when combined with the uL of water. The i5 index and the
i7 index from the dual indexing library prep is also provided.
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All of the 29 freshly pulled samples appeared to have
successful library preparations with the exception of three samples
(199-201) which were all prepared by the BYU student Health
center on the same day, suggesting issues with their preparations.
All samples except these three were diluted and combined in a 1
nM pool with the 14 samples indicated in Table 4.2 and sequenced
using 151 bp pair-end sequencing on the Illumina iSeq 100.
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The iSeq reported excellent statistics for the iSeq100 (Q30
Read 1, 89.6%, Q30 Read 2 87.9%, % Cluster PF 62.6%, %
Occupancy 86.9%), however no reads were obtained for any of the
samples suggesting the wrong indexes were input. The IDT library
manual had stated to use the reverse complement of i5 primer
(which provides the paired end, second strand sequencing),
however close inspection of the iSeq output indicated that the i5
primer should actually have been inputted in the forward direction.
Reprocessing of the run yielded excellent results, with hundreds of
thousands of reads per sample.
Assembly of SARS-CoV-2 genomes isolated from the BYU
Student Health center
Assembly was performed using Geneious Prime 2022.2
specific specifications are listed in the methods section under
“Assembly of SARS-CoV-2 genome”. Quality trimming and removal
of left end amplicon primer sequences were performed prior to
assembling to the original Wu-Han (MN908947) whole genome
sequence pulled from NCBI. Once assembling to the Wu-Han
isolate, consensus sequence generation was performed after
analyzing high and low coverage areas. Areas of low coverage
(less than 10) were marked with an N to avoid improper nucleotide
labeling.
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Variant analysis SARS-CoV-2 genomes isolated from the BYU
Student Health center & Sewage Samples
We ran the assembled consensus sequences through
Clustal Omega Multiple Sequence Alignment tool (Clustal Omega,
www.ebi.ac.uk/Tools/msa/clustalo/). Using the alignment results we
were able to configure a phylogenetic cladogram of the isolates
(Fig. 4.3).

Figure 4.3 Clustal Omega Phylogenetic Cladogram of SARS-CoV-2
positive isolates. Each Bracket represents a set to be analyzed and
categorized. Colors Represent years in which the samples were
collected. We see that most year samples stay together.
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From the results, we can see direct relations among the
samples. The samples in closest relation to the Wu-Han strain

(sample numbers

187, 188, 193,192) all are from early 2021 which makes the tree
look promising. However, samples from various years get crossed
in other sections of the diagram (such as sample 216 from 2021
coming after a sample from 2022). Of course, the program is using
these consensus sequences to the best of its ability, so to confirm
these results being conclusive of a variant progression through
different stages of the cladogram, the next step is to analyze the
alignment.
To do this, we used Clustal Omega again, but then input the
reading into NCBI’s Multiple Sequence Alignment Viewer to identify
nucleotide differences more easily in hopes to see variant changes.
Anchoring was made to the Wu-Han sequence (MN908947) to see
possible variant changes in the samples from the original strain.
Sequences were ordered by the Clustal Omega alignment to the
Wu-Han sequence, meaning that the outside edges should be most
dissimilar, and that the bottom would be most dissimilar to the WuHan strain.
For each main SARS-CoV-2 variant from the COVID-19
pandemic (Fig. 2.2), we pulled the main mutations present within
the spike protein of the variant sequence (Table 4.4) since literature
has shown it to be the most identifiable feature for SARS-CoV-2
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variants (21). We then proceeded to search through our strains to
see if the specified mutation was present in or near the
corresponding base pair.
Table 4.4 List of Spike Mutations Listed by Variant type. The first
column shows the specific variant ID, while the second column
displays the amino acid change occurring within the Spike Gene.
The final column shows the corresponding BP. associated with the
amino acid change for the entire sequence rather than just the
gene sequence.
VARIANT AMINO ACID

CORRESPONDING BP.

CHANGE
Alpha

A570D

23273

Alpha

P681H

23606

Alpha

T716I

23711

Alpha

S982A

24509

Alpha

D1118H

24917

Alpha

H69-V70del

21770

Alpha

Y144del

21995

Beta

L18F

21617

Beta

D80A

21803

Beta

D215G

22208
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Beta

R246I

22301

Beta

K417N

22814

Beta

E484K

23015

Beta

D614G

23405

Delta

L18F

21617

Delta

D80A

21803

Gamma

N969K

24470

Omicron

G142D

21989

Omicron

G339D

22580

Omicron

S371L

22676

Omicron

S373P

22682

Omicron

S375F

22688

Omicron

N440K

22883

Omicron

S477N

22994

Omicron

Q493R

23042

Omicron

Q498R

23057
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Omicron

Y505H

23078

Omicron

N679K

23600

Omicron

N764K

23855

Omicron

D796Y

23951

Omicron

Q954H

24425

Omicron

N969K

24470

As we looked through the sequence alignments, we charted
which sample sequence was displaying that particular amino acid
change making a chart in which we can see the RNA sample ID,
the date that the sample was collected, and the variant mutations in
each sequence (Table 4.5, Fig. 4.3).
From the Chart we can see that there are several
samples that display various mutations that align with specific
variants. In order to classify them (since many have overlap) we
decided that any displaying a mutation directly indicative of the
variant, we would classify it as such. But if a sample displayed
more than one mutation from different variants, we would classify it
as the variant in which it displayed the most mutations.
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Table 4.5 Table of Samples and Mutations found in the Consensus
Sequence. Columns are RNA ID, Date of Sample Collection, and a
list of each variant specific mutation ordered as above. Rows are
sample numbers. “Y” indicates the mutation being found in the
particular sample. “N” indicates that there were gaps where we
were looking.
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Figure 4.3 Using NCBI’s Multiple Sequence Alignment Tool to show
nucleotide mutations between Variants in the SARS-CoV-2
Samples. Red markings highlight a nucleotide change from the WuHan anchor. A) Here we see that bp 21617 has a base pair
change from C to G, indicating a possible L18F mutation as would
be seen in the spike genome of either the Beta or Delta variant,
thus samples 212, 209, 207, and Sewage sample 1 (S1) are
displaying Beta or Delta mutation. B) Here we see that bp 21989
has a base pair change from G to A, indicating a possible G142D
mutation in the spike genome as would be seen in the Omicron
variant, thus samples 212, 208, 210, 209, 207, 183, 198 and
Sewage Sample 1 (SA) are displaying Omicron variant mutation.
C)Here we see that bp 22883 has a base pair change from T to G,
indicating a possible N440K mutation in the spike genome as would
be seen in the Omicron variant, thus samples 189, 185, 204, 205,
194 and are 22 are displaying Omicron variant mutation. D) Here
we see that bp 24509, 24917, and 23711 have base pair changes
that indicate possible S982, D1118H, and T716I spike genome
mutations (respectively), as would be seen in the alpha variant,
thus due to 214 displaying all three vital and relevant alpha
mutations, we have identified sample 214 to be an alpha variant.
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Conclusions
Based on the analysis of the Clustal Omega Phylogenetic
Cladogram and the datum collected from the variant analysis based
off the NCBI Multiple Sequence Alignment Tool, we can see
interesting correlations between the variant mutations and the
COVID-19 variant timeline (Fig. 2.2).
Looking at the Phylogenetic Cladogram, Bracket A, we see
that our Wu-Han whole genome strain (MN908947) that we used as
reference is closely related to samples 192, 193, 187, 188 and 218
that were collected between March and April of 2022. All of these
samples showed no significant changes to the sequence and thus
can be assumed to be the original genotype of SARS-CoV-2 which
explains their direct relation to our reference genotype.
Bracket B of the Cladogram, features samples (bottom to
top) 227,226,228,197,224, S2, and 223. These samples were
collected at various times between March 2021 and February 2022,
but they show no significant mutations to indicate a specific
variance. Sewage sample 2 (S2) was collected from August 2021,
and showed no variance in its sequence either, meaning that most
likely at that time of year for our sewage sample pull, there were
very few variations from our Wu-Han strain at this period of time in
the local population.
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Bracket C of the Cladogram, features samples (bottom to
top) 214,195, 206, 229, 222,196,194, 185, 205,189, 204,186, 203,
221, 230, and 216. 214 from March 2021 has been classified as our
only alpha variant, which explains why it not only closely resembles
our Wu-Han strain, but also is in its own defined bracket. The next
couple of steps in we see samples 206, 196, and 186 which have
been identified as gamma variants. The other samples in this
section (229, 222,195,185, 205, 189, and 204) have been identified
as Omicron variants that also have the gamma mutation. All these
samples have been collected from 2022 which makes sense with
the timeline why so many would identify as gamma and Omicron.
In Bracket D we have 4 samples, 203 which bears the
closest relation to Beta or Delta variant, 221 which is Omicron
variant, 230 which is closest to Alpha variant, and 215 which is also
closest to Alpha. The primary difference that we can see in this
section is that all are Alpha or Omicron with only 216 being from
March 2021 while the rest are pulled from Feb 2022. It is interesting
how an omicron can bear close resemblance to both alpha and
gamma variants (as discussed in Bracket C). Overall, the
resemblance makes sense aside from the year distribution which
would denote the relativity that clustal created, but it does show
tight correlations between the mutations themselves.
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In Bracket E we see the rest of the variants which all come
from 2021 aside from sewage sample 1 (S1) from March 2022. All
of these variants in this bracket are most closely related to the
Delta or Beta variant though it is hard to tell which for each of them.
The Delta and Beta variants have very slight mutations compared
to the rest of the variants so it makes sense that they would be
grouped together. Sewage sample 4 was from November 2021
along with all the other samples being from the latter half of the
year of 2021. This shows a high correlation to beta/delta being
associated with the last half of 2021.

59

CHAPTER 5 Methods
Sample Collection
The sample collection for this study had already been
completed. Our study contains positive SARS-CoV-2 samples that
have been obtained from the Brigham Young University Student
Health Center on-site COVID-19 nasal swab or saliva testing (~100
samples) from January 2021 - March 2022. In addition, we have
sewage samples collected fresh between April 2021 and March
2022 from Provo Wastewater Treatment Plant raw influent.
We collected and isolated the SARS-CoV-2 RNA from
wastewater sewage. The samples were collected fresh onsite from
the Provo Sanitation Wastewater Treatment Plant’s raw influent.
Because the RNA is highly unstable in wastewater (11), we
performed ZYMO Environ Water RNA extraction protocol within 30
minutes of the sample taken. Because SARS-CoV-2 RNA would
not be the most prevalent RNA in the sample, we decided to double
the expected aliquot amount and treat it as two separate samples
that we would then combine during homogenization to create a
single more condensed sample. To ensure better quality of RNA we
worked in a biosafety cabinet, used filter tips, and sprayed
everything with RNaseZAP to better uphold RNA stabilization. After
we isolated the SARS-CoV-2 RNA, the sample was kept in a -80° C
freezer.
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Sample Preparation and Sequencing Methods
Sequencing was performed using Next Generation Illumina
MiSeq using IDT xGen SARS-CoV-2 Gene Amplicon Panel. Prior to
sequencing Reverse Transcriptase PCR (RT-PCR) was performed
on 148 BYU Student Health center positive samples chosen
randomly via computer algorithm and 4 Provo Wastewater
extracted RNA samples from May 2021, September 2021, January
2022, and April 2022. These points were chosen for the variant
spikes associated with each of the months. May being the
beginning of COVID-19, September to document the after-summer
spike, January for after Omicron, and April for a more recent
analysis.
We used ThermoFisher Scientific SuperScript IV VILO
Master Mix and its specified first strand synthesis protocol on all
collected samples. We also tried MMLV reverse transcriptase
(Takara BioTech) on a subset of 14 samples to compare reverse
transcriptase efficiencies. We then proceeded to perform
multiplexed PCR protocol as described in xGen SARS-CoV-2 Gene
Amplicon Panel Appendix C (IDT) for Low viral load input
recommendations. The only difference being that we changed 24
cycles recommendation to 28 to increase the PCR product. For
Indexing PCR, we followed the Appendix C Low Viral Load protocol
for performing low viral load indexing PCR in Appendix C.
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For the Illumina MiSeq and iSeq settings we kept everything
standard with 151 bp paired end base pair reads. Libraries were
denatured in NaOH and diluted to 20 pM for the MiSeq loading (800
uL loaded) and loaded straight at a concentration of 150 pM for the
iSeq (20 uL loaded).
Assembly of SARS-CoV-2 genomes
Genomes were assembled using Geneious Prime 2022.2.
Quality trimming and removal of left end amplicon primer
sequences were performed using the BBDuk plugin with Kmer
length at 21, allowing for 3 maximum substitutions, trim low-quality
set to 20, and discard short reads set to 75 bp. We also used
custom commands “rcomp=f restrictleft=32” to ensure only forwardfacing primers at the start of the read are trimmed. The reference
genome for SARS-CoV-2 was obtained from NCBI, accession
MN908947. In order to properly map the trimmed reads to the
sequence, we set the “Map to Reference” sensitivities to low by
using “only map paired read which map nearby” and allowing a
maximum gap of 50 while iterating 3 times. Consensus sequence
generation was performed after using Geneious “Find
Variations/SNPs” and “Find High/Low Coverage” to produce the
consensus sequence where low coverage sights less than 10 to be
marked with an N.
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Analysis and comparison of SARS-CoV-2 genomes
Analysis and comparisons were run using Clustal Omega to
identify phylogeny and alignment of the final sequence samples.
The alignment files were then copied to the NCBI Multiple
alignment viewer in order to do direct comparisons between sample
nucleotide changes and placements. The Wuhan Isolate, accession
MN908947, was used as the anchor sequence for alignment in all
sample analysis. We then used Table 4.4 to list mutations that we
would be able to see in the spike protein of the samples and then
analyzed them to see if they follow a particular mutation type for a
specific variant.
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CHAPTER 6 Conclusions
In the short term, our results should aid the WHO in
cataloging SARS-CoV-2 variants, improving our understanding of
its evolution. BYU provides a unique opportunity due to the
abundance of students who travel for spring or winter break,
possibly bringing a variety of strains to our campus. Our long-term
goal of this study was to design primers for QPCR that would
enable long range quantification of SARS-CoV-2 variant frequency
alterations in BYU’s collection of frozen sewage samples which
spans from the beginning of the COVID-19 pandemic. Though we
were not able to fulfill that long term goal, we were able to
sequence the frozen sewage and positive COVID-19 samples from
the BYU Student Health Center through ARTIC sequencing.
From the samples we were able to learn the BYU campus
local populations variant timeline. As we saw from the phylogenetic
cladogram (Fig. 4.3), there are obvious clusters of specific strains
that have close relations to each other. Beta and Delta are highly
related and share similarities closer to the original variant than
Alpha, Gamma, and Omicron. Gamma and Omicron had a lot more
similarities than Gamma and Alpha, allowing various mixes of their
mutations to interweave their consensus code. This allowed
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Omicron to group more with Gamma than Alpha, letting the pure
alpha variant to be on its own and show similarities to the original
strain.
The positive Student Health Center samples followed the
timeline that was proposed in the introduction (Fig. 2.2), only taking
place one year later when it finally hit our local population in full.
This can be seen not only in the 2021 samples having different
variants in the beginning of the year than the end, but also for the
2022 Omicron outbreak (Fig.6.6). As we can see, our timeline
keeps Beta as the primary constant since 2021, while alpha
remained in the population during that time as well. By late 2021,
we see that Delta is current in the population, but within a couple of
months since Omicron is introduced, we see it completely
overpower the population, even resulting in the Sewage consensus
sequence looking like Omicron mutations.

Figure 6.1 Timeline of Variants collected and analyzed in the local
population from March 2021-April 2022.
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The Beta variant seen in February is most likely due to gaps
in the reads as documented in Table 4.5. Most likely these would
be Omicron variant, but because we didn’t want to assume they
remain red in the figure.
Sewage samples also showed similar behaviors with their
mutations, though none of them strictly aligned to any one variant
other than March 2022 which aligned most similar to Omicron.
From this, we learn that sewage samples can be sequenced and
analyzed to produce a low concentration timeline of potential
variants.
In order to answer our broader question that we posed at the
beginning, whether intestinal or Asymptomatic COVID-19 is caused
by a specific variant or someone’s own unique physiology, the
Sewage Contigs should be examined to look for unique changes
along the spike protein or examined to see if any of them follow a
specific trend in variant progression.
Other things that should be done for future research would
be to find a better way to create a phylogenetic tree. Due to gaps in
our reads from sequencing the whole genome, our phylogenetic
tree was unable to read around them causing it to be biased due to
the gaps. We would want to make another tree that reduces the
penalty for gaps in order to create a better outlook on the relativity
of these variants.
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